Ironwood Pharmaceuticals, Inc.
IRWD
$0.7267
-$0.0233-3.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 90.55M | 91.59M | 94.40M | 74.88M | 117.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 90.55M | 91.59M | 94.40M | 74.88M | 117.55M |
| Cost of Revenue | -78.48M | 29.83M | 30.39M | 25.82M | -59.26M |
| Gross Profit | 169.02M | 61.77M | 64.01M | 49.06M | 176.81M |
| SG&A Expenses | 33.59M | 36.11M | 36.56M | 37.61M | 46.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.98M | 65.94M | 66.95M | 63.42M | 86.34M |
| Operating Income | 31.56M | 25.65M | 27.44M | 11.46M | 31.21M |
| Income Before Tax | 24.00M | 17.37M | 18.88M | 4.96M | 30.36M |
| Income Tax Expenses | 21.74M | 13.72M | 19.74M | 9.12M | 32.11M |
| Earnings from Continuing Operations | 2.26M | 3.65M | -860.00K | -4.16M | -1.75M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 658.00K |
| Net Income | 2.26M | 3.65M | -860.00K | -4.16M | -1.09M |
| EBIT | 31.56M | 25.65M | 27.44M | 11.46M | 31.21M |
| EBITDA | 32.05M | 26.56M | 27.55M | 11.97M | 31.72M |
| EPS Basic | 0.01 | 0.02 | -0.01 | -0.03 | -0.01 |
| Normalized Basic EPS | 0.09 | 0.07 | 0.08 | 0.02 | 0.10 |
| EPS Diluted | 0.01 | 0.02 | -0.01 | -0.03 | -0.01 |
| Normalized Diluted EPS | 0.09 | 0.07 | 0.08 | 0.02 | 0.10 |
| Average Basic Shares Outstanding | 159.45M | 159.71M | 159.01M | 157.70M | 156.01M |
| Average Diluted Shares Outstanding | 159.45M | 160.23M | 159.01M | 157.70M | 156.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |